Nuwellis
- Country
- Ownership
- -
- Employees
- 59
- Market Cap
- -
- Introduction
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Clinical Trials
9
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- Conditions
- Heart Failure (for Example, Fluid Overload)Heart FailureFluid Overload
- Interventions
- Device: Aquadex Smartflow® SystemDrug: IV Loop Diuretics
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Nuwellis, Inc.
- Target Recruit Count
- 372
- Registration Number
- NCT05318105
- Locations
- 🇺🇸
Banner Health, Tucson, Arizona, United States
🇺🇸MemorialCare, Long Beach Medical Center, Long Beach, California, United States
🇺🇸Sharp Memorial Hospital, San Diego Cardiac Center, San Diego, California, United States
Ultrafiltration Therapy Registry Using Aquadex (ULTRA-Peds)
- Conditions
- Fluid Overload
- First Posted Date
- 2020-11-25
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Nuwellis, Inc.
- Target Recruit Count
- 97
- Registration Number
- NCT04644731
- Locations
- 🇺🇸
Children's of Alabama Hospital, Birmingham, Alabama, United States
🇺🇸Lucile Packard Children's Hospital Stanford, Palo Alto, California, United States
🇺🇸Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
A Feasibility Study on Ultrafiltration and Blood Volume Measurements
- Conditions
- Acute Decompensated Heart FailureFluid Overload
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Nuwellis, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04241718
- Locations
- 🇺🇸
Midwest Cardiovascular Institute, Naperville, Illinois, United States
C-Pulse® System European Multicenter Study
- Conditions
- Heart Failure
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Nuwellis, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT01872949
- Locations
- 🇦🇹
University Hospital, Innsbruck, Austria
🇩🇪Evangelisches Krankenhaus Niederrhein, Duisburg, Northrhine-Westfalia, Germany
🇩🇪Cardio-Centrum Berlin, Berlin, Germany
C-Pulse® System: A Heart Assist Device Clinical Study
- Conditions
- Heart Failure
- First Posted Date
- 2012-12-04
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Nuwellis, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT01740596
- Locations
- 🇺🇸
The University of Alabama at Birmingham Hospital, Birmingham, Alabama, United States
🇺🇸University of Southern California Keck School of Medicine, Los Angeles, California, United States
🇺🇸University of California San Francisco, San Francisco, California, United States
- Prev
- 1
- 2
- Next
News
Nuwellis Terminates REVERSE-HF Clinical Trial to Refocus on Outpatient Heart Failure Market
Nuwellis announced the termination of its REVERSE-HF clinical trial, which was evaluating ultrafiltration versus IV loop diuretic therapy for hospitalized heart failure patients.